- Home
- ESEA vs ALT Comparison
ESEA vs ALT Comparison
Compare ESEA & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESEA | ALT |
|---|---|---|
| Founded | 2005 | 1997 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 389.3M | 415.3M |
| IPO Year | 2005 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ESEA | ALT |
|---|---|---|
| Price | $63.00 | $3.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $62.00 | $15.50 |
| AVG Volume (30 Days) | 59.2K | ★ 2.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.59% | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | $1.49 | N/A |
| Revenue Next Year | N/A | $756,308.50 |
| P/E Ratio | $3.39 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $26.30 | $2.91 |
| 52 Week High | $72.87 | $7.73 |
Technical Indicators
Market Signals| Indicator | ESEA | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 49.97 | 33.42 |
| Support Level | $51.63 | $3.40 |
| Resistance Level | $65.17 | $4.25 |
| Average True Range (ATR) | 3.68 | 0.24 |
| MACD | -0.43 | -0.06 |
| Stochastic Oscillator | 25.03 | 7.07 |
Price Performance
Historical ComparisonAbout ESEA Euroseas Ltd. (Marshall Islands)
Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes, providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.